Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for TriSalus Life Sciences's Equity-to-Asset or its related term are showing as below:
TLSI'
s Equity-to-Asset Range Over the Past 10 Years
Min: -9.3 Med: -1.02 Max: 0.25
Current: 0.18
During the past 5 years, the highest Equity to Asset Ratio of TriSalus Life Sciences was 0.25. The lowest was -9.30. And the median was -1.02.
TLSI's Equity-to-Asset is ranked worse than 88.98% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.65
vs TLSI: 0.18
TriSalus Life Sciences (NAS:TLSI) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
TriSalus Life Sciences Equity-to-Asset Related Terms
TriSalus Life Sciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for TriSalus Life Sciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TLSI vs TMCI, LAB, SENS: Equity-to-Asset Comparison
For the Medical Devices subindustry, TriSalus Life Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's Equity-to-Asset falls into.
TriSalus Life Sciences Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
TriSalus Life Sciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences (TLSI) has a Equity-to-Asset of 0.18 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on TriSalus Life Sciences and its competitors. According to the industry distribution chart, TriSalus Life Sciences ranks #759 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 89%.
Is TriSalus Life Sciences' Equity-to-Asset too high?
TriSalus Life Sciences' current Equity-to-Asset is 0.18. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. TriSalus Life Sciences' value of 0.18 is 72.3% below this industry median. Based on the distribution chart, TriSalus Life Sciences ranks #759 out of 853 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TriSalus Life Sciences has a GF Score™ of 29/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' Equity-to-Asset compare to TMCI and LAB?
According to the Medical Devices & Instruments industry distribution chart, TriSalus Life Sciences ranks #759 out of 853 companies for Equity-to-Asset. This places TriSalus Life Sciences in the lower half of its industry. The industry median Equity-to-Asset is 0.65. TriSalus Life Sciences' value of 0.18 is 72.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TriSalus Life Sciences's current Equity-to-Asset of 0.18 is 72.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on TriSalus Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TriSalus Life Sciences's current Equity-to-Asset is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Fairly Valued. The stock's GF Value™ is $4.30, compared to a current price of $4.25 — trading 1.2% below its estimated fair value. The current Equity-to-Asset is 0.18 and 72.3% below the Medical Devices & Instruments industry median of 0.65. TriSalus Life Sciences' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current Equity-to-Asset is 0.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TriSalus Life Sciences (TLSI) Overvalued in 2026?
Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be undervalued.
The current stock price of $4.25 is trading 1.2% below its estimated GF Value™ of $4.30.
GuruFocus considers TriSalus Life Sciences to be Fairly Valued.
Key valuation signals for TLSI:
Equity-to-Asset: 0.18
GF Value™: $4.30 vs. price of $4.25 (1.2% below fair value)
Industry Position: 72.3% below the Medical Devices & Instruments median (#759 of 853)
No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
29GF Score
Get the complete analysis for TLSI
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSI has been successfully added to your 
